Why did HER2 NSCLC spread to my liver at 50?

Question

Hello doctor,

I am a 50-year-old female, weighing approximately 148 pounds. I was recently diagnosed with HER2 mutation NSCLC with liver metastasis.

My current issues include fatigue, mild abdominal discomfort, and a noticeable loss of appetite. I want to know the following:

My doctor mentioned targeted therapy options, but I am confused. Why did the HER2 mutation cause NSCLC to spread to the liver at age 50?
Is this mutation linked with faster spread or specific organs?

Please suggest.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

Thank you for reaching out.

I am really sorry you are going through this. It is completely natural to feel confused and worried after a diagnosis like this.

At 50, being told you have HER2 (human epidermal growth factor receptor 2) mutated non-small cell lung cancer (the most common type of lung cancer, which usually grows and spreads more slowly than small cell lung cancer) with liver involvement can feel overwhelming, especially with so many new medical terms.

The HER2 mutation itself did not directly cause the cancer to spread to your liver. It acts like a constant switch inside the cancer cells that keeps telling them to grow and divide. Because of this, the tumor can become more active over time.

When lung cancer spreads, it usually travels through the bloodstream. The liver is one of the most common places it can reach, not because of HER2 specifically, but because the liver receives a large amount of blood flow from the body. In non-small cell lung cancer, common sites of spread include the liver, bones, brain, and adrenal glands, regardless of the mutation type.

It is also important to understand that having a HER2 mutation does not automatically mean the cancer will spread faster or behave more aggressively. What it does do is help your doctors choose the most appropriate treatment for you.

This is actually an advantage in your case. HER2 is a targetable mutation, which means there are treatments designed specifically to block this pathway. These targeted therapies are often more precise than traditional chemotherapy and can be more effective for tumors with this mutation. This is likely why your oncologist has discussed targeted therapy options.

Regarding your current symptoms of fatigue, loss of appetite, and mild abdominal discomfort, these are quite common in people with liver involvement and cancer in general. Many patients notice that these symptoms improve once treatment starts and begins to work.

The most important step now is to begin the treatment your oncologist has recommended and continue with regular follow-up. This helps monitor how well the treatment is working and allows timely adjustments if needed.

You are not alone in this. There are effective treatment options available, and identifying this mutation gives your care team a clearer direction for your treatment.

I hope this helps.

Please revert in case of further queries.

Thank you.